Preparing for the Future of Rare Diseases
The rare disease market is one of the fastest-growing therapeutic market sectors due to favorable government policies and the increasing numbers of rare disease cases globally.
While a rare disease is defined as a condition that affects less than 200,000 people in the United States, it is estimated that more than 300 million people suffer from rare diseases globally. Shockingly, more than 70% of rare diseases do not have a treatment, suggesting a relatively untapped market.
Our panel of experts will discuss the different approaches to rare disease therapeutics including IP considerations, the different types of therapeutics available, what investors look for in early-stage therapeutics and what resources are available for academic labs studying rare diseases.
Moderator:
Patrick Kelly, PhD, JD, Counsel, Stradley Ronon
Panelists:
Marni Falk, MD, Executive Director, Mitochondrial Medicine Frontier Program, Distinguished Chair in the Department of Pediatrics, The Children’s Hospital of Philadelphia
Dalfoni Banerjee, Principal Consultant & CEO, 3Sixty Pharma Solutions LLC
Ihor Terleckyj, PhD, Principal, Valhalla Consulting Group, Catalyst Pharma
